Fundraising

Bispecific antibodies
#Bispecific Antibodies #Boulevard Bio #Fundraising #Monoclonal antibodies #Start-ups

Multi-specific antibody company launches with $65 million

Boulevard Bio has emerged from stealth with $65 million from founding investor Deerfield Management and early Phase I healthy volunteer data for lead candidate BLVD101.   Founded by pioneers in B cell biology and incubated by Deerfield Management within Deerfield Discovery and Development (3DC), Boulevard’s approach is grounded… Read More

#Business & Investment #News

#CellCentric #Fundraising #Oncology #T cell engagers

CellCentric raises $220m to advance trials of oral myeloma drug

CellCentric has completed an oversubscribed $220 million Series D financing led by Venrock Healthcare Capital Partners, with participation from new and existing investors.  The proceeds will support clinical trials for multiple myeloma therapy inobrodib. These will include continued enrolment of the company’s Phase II DOMMINO-1 study and… Read More

#Business & Investment #News #Trending News

Woman standing on scales
#Fundraising #Metabolic diseases #Obesity #Pila Pharma #Weight loss

Pila Pharma raises SEK 30 million to fund obesity studies

Biotech company Pila Pharma has recently completed a strongly oversubscribed share issue on Nasdaq First North in Stockholm.   The company says the raised capital of nearly SEK 30 million ($3 million) will finance the first steps of development of its tablet-based treatment for obesity.  Founded… Read More

#Business & Investment #News

GBP pound sterling funding
#Biotechnology #Financing #Fundraising #Oncology

Trogenix secures £70m to advance oncology pipeline

Biotech company Trogenix has secured £70 million ($95 million) in funding to help advance its pipeline of cancer therapies.   The Series A funding was led by IQ Capital and invested in by 4BIO Capital, alongside new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital. The… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Automation #Automation / robotics #Fundraising #Potato

Autonomous science agent company closes $4.5m seed round

Potato, a technology company focused on building autonomous science agents, has announced $4.5 million in new funding, led by Draper Associates.   The company says the funds will accelerate its mission to automate scientific research.   Potato’s AI agents orchestrate scientific workflows and use tools to execute… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Drug discovery #Fundraising #Isomorphic Labs

Isomorphic Labs raises $600m to support AI drug design

Isomorphic Labs has raised $600 million towards its ambition to leverage AI to reimagine and accelerate drug discovery.   The financing round was led by Thrive Capital, with participation from GV, and follow-on capital from existing investor Alphabet.  Isomorphic Labs aims to apply its AI drug… Read More

#Business & Investment #News

#Biotechnology #Europe #Fundraising

Europe’s largest biotech fund exceeds target with €165m

Sofinnova Biovelocita II has exceeded its target, successfully raising €165 million, with substantial backing from global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures.   The milestone marks a significant expansion of Sofinnova Partners’ biotech acceleration strategy, extending beyond Italy to include France, the UK, and… Read More

#Business & Investment #News

#Epigenomics #Financing #Fundraising #Tune Therapeutics

Tune raises $175m to support epigenome editing programmes

Epigenome editing company Tune Therapeutics has announced the completion of over $175 million in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation.  Tune Co-Founder Dr Charles Gersbach, whose research at Duke University formed the basis for Tune’s TEMPO epi-editing platform, commented: “Tune has… Read More

#Business & Investment #News

#Business #Financing #Fundraising #Investment

New DDW Highlights podcast: 13 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news round-up at the end of last year focused on drug… Read More

#News

#Business #Financing #Fundraising #Investment

This week in drug discovery (6-10 January) 

News round-up for 6-10 January by DDW Senior Digital Content Editor Diana Spencer. Our news round-up at the end of last year focused on drug discovery investment, so it is positive to see that this has also started strong in 2025, with a number of new acquisitions, research… Read More

#News

#Business #Financing #Fundraising #Investment

Listen now: Last DDW Highlights episode of 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we approach the end of 2024, it’s great to see that… Read More

#News

#Business #Financing #Fundraising #Investment

This week in drug discovery (16-20 December) 

News round-up for 16-20 December by DDW Senior Digital Content Editor Diana Spencer. As we approach the end of 2024, it’s great to see that investment in drug discovery is still going strong, with an impressive $300 million raised by AI-focused company SandboxAQ and another significant financing by… Read More

#News

#Adcendo #Antibody drug conjugate (ADC) #Financing #Fundraising

Adcendo raises $135 million to advance ADC pipeline

Biotech company Adcendo has announced the successful closing of an oversubscribed $135 million Series B financing round.   Proceeds from the fundraise will be used to accelerate the development of the company’s ADC pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programmes. … Read More

#Business & Investment #News